Actively Recruiting
The Real-world Treatment Satisfaction by Gefapixiant in RCC
Led by Nagoya City University · Updated on 2025-01-29
63
Participants Needed
2
Research Sites
81 weeks
Total Duration
On this page
Sponsors
N
Nagoya City University
Lead Sponsor
M
Merck Sharp & Dohme LLC
Collaborating Sponsor
AI-Summary
What this Trial Is About
Chronic cough has a high global prevalence and it is refractory to such treatments by approximately 20% of patients. Gafapixant is a P2X3 receptor antagonist that has demonstrated the reduction of cough in patients with refractory chronic cough(RCC). Taste disturbance is the most frequent adverse event by gefapixant (approximately 60-70%). Although gefapixant is well-tolerated even if taste disturbance has occurred, the impact of taste disturbance on cough-specific QoL remains to be unclear. Therefore, the investigator would like to evaluate factors related to treatment satisfaction by gefapixant in RCC patients. the investigator hypothesize that taste disturbance will be associated with the improvement of cough specific QoL and treatment satisfaction in RCC patients.
CONDITIONS
Official Title
The Real-world Treatment Satisfaction by Gefapixiant in RCC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients with refractory chronic cough (RCC) or unexplained chronic cough (UCC) lasting 8 weeks or more
- Cough that has not improved despite intensive treatments for its cause
- Never smokers or ex-smokers with a smoking history of 20 pack-years or less
You will not qualify if you...
- Patients with lung cancer, interstitial lung diseases, bronchiectasis, or respiratory infections such as tuberculosis or acute pneumonia
- Current smokers, ex-smokers with a smoking history of more than 20 pack-years, or those who quit smoking within six months before starting gefapixant
- Pregnant individuals
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Nagoya City University
Nagoya, Aichi-ken, Japan, 467-8601
Not Yet Recruiting
2
Nagoya City University Hospital
Nagoya, Aichi-ken, Japan, 4678601
Actively Recruiting
Research Team
Y
Yoshihiro Kanemitsu, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here